StockNews.com Begins Coverage on Enzo Biochem (NYSE:ENZ)

Research analysts at StockNews.com initiated coverage on shares of Enzo Biochem (NYSE:ENZ) in a research note issued on Friday. The brokerage set a “hold” rating on the medical research company’s stock.

Enzo Biochem Stock Down 1.7 %

NYSE:ENZ opened at $0.69 on Friday. Enzo Biochem has a twelve month low of $0.68 and a twelve month high of $1.44. The stock’s 50-day simple moving average is $0.94 and its 200 day simple moving average is $1.06.

Enzo Biochem (NYSE:ENZ) last issued its earnings results on Monday, December 16th. The medical research company reported ($0.05) earnings per share for the quarter. Enzo Biochem had a negative net margin of 81.73% and a negative return on equity of 11.84%.

Institutional Trading of Enzo Biochem

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ENZ. Geode Capital Management LLC lifted its position in shares of Enzo Biochem by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock valued at $413,000 after acquiring an additional 11,742 shares during the period. XTX Topco Ltd raised its holdings in shares of Enzo Biochem by 94.5% during the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 13,735 shares during the period. Renaissance Technologies LLC boosted its position in shares of Enzo Biochem by 2.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after purchasing an additional 64,417 shares in the last quarter. Finally, BBR Partners LLC acquired a new stake in shares of Enzo Biochem in the 3rd quarter valued at about $112,000. Institutional investors and hedge funds own 36.90% of the company’s stock.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.